Glecaprevir/pibrentasvir + sofosbuvir for post-liver transplant recurrent hepatitis C virus treatment.

Glecaprevir/pibrentasvir in combination with sofosbuvir may serve as a safe and effective option for treatment of recurrent hepatitis C virus post-liver transplant in patients who previously failed direct-acting antivirals.
Competing Interests: Conflict-of-interest statement: Martin MT and Patel S serve on the speakers’ bureau for AbbVie and Gilead. Martin MT has received grant funding from Gilead and Merck, served on the advisory board for AbbVie and Gilead, and is a minor shareholder of AbbVie, Gilead, and Merck stock.
(©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.)